| Document |
Document Title |
|
WO/2019/227526A1 |
Provided is a fluorescently labelled nucleotide having a structure represented by formula I. The fluorescently labelled nucleotide is linked by a covalent bond between deoxyribonucleoside triphosphate and a fluorescent dye molecule and i...
|
|
WO/2019/228319A1 |
The present invention belongs to the field of medical technology and relates to an intestinal MCT1 carrier protein design-based prodrug and a preparation method therefor, and in particular relates to a preparation method for a short-chai...
|
|
WO/2019/226952A1 |
An oligo- or polynucleotide analogue having one or more structures of the general formula: where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is used for treating obesity-related metabolic diseases.
|
|
WO/2019/226755A1 |
The present invention relates to amino acid salts of nicotinic acid ribosides and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: wherein M1, R1, R2, and R3 are a...
|
|
WO/2019/224172A1 |
The present invention relates to the manufacture of allofuranose from glucofuranose as defined in the description and in the claim. Allofuranos is an intermediate in the manufacture of oligonucleotides which can be used as a medicament.
|
|
WO/2019/219070A1 |
The present invention belongs to the field of medicinal chemistry and relates to a deuterated oligonucleotide and a prodrug. In particular, the present invention relates to a compound represented by formula I or a pharmaceutically accept...
|
|
WO/2019/219895A1 |
The present invention relates to crystalline (thio)nicotinamide ribofuranoside salts, methods of making such crystalline salts, a pharmaceutical composition comprising same, and use of said crystalline salts as nutritional (dietary) supp...
|
|
WO/2019/221024A1 |
[Problem] To develop a purine base derivative. [Solution] A guanosine derivative compound characterized by being represented by the formula, wherein one of R1 and R2 is H and the other is any of H, OH, OCH3, and F, R3 is any of a compoun...
|
|
WO/2019/222368A1 |
The present invention relates to amino acid salts of nicotinic acid mononucleotides and nicotinamide mononucleotides and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in...
|
|
WO/2019/222500A1 |
Methods of modulating the activity of a cyclic dinucleotide (CDN) in a cell via membrane transporter are provided. Aspects of the methods may include contacting a cell with a CDN transporter-modulating agent to modulate transport of a CD...
|
|
WO/2019/217470A1 |
Automated oligonucleotide synthesis-compatible sulforhodamine dye phosphoramidite compounds and labeled polynucleotides incorporating these dyes are provided.
|
|
WO/2019/213756A1 |
Compounds are described which include polyvalent ligands linked to a cyclodextrin scaffold which exhibit strong binding affinities for lanthanides and favorable characteristics with respect to altering the relaxation time of coordinated ...
|
|
WO/2019/211799A1 |
The present disclosure relates to 2'3'-cyclic dinucleotides comprising a carbocyclic nucleotide and derivatives thereof, that can modulate the activity of the STING adaptor protein.
|
|
WO/2019/204869A1 |
The present invention relates to improved prodrugs, and compositions thereof. In particular, it relates to amphiphilic gemcitabine prodrugs or amphiphilic prodrugs of other biologically active molecules with the capacity to make liquid c...
|
|
WO/2019/209840A1 |
Provided herein are methods and compositions related to treating and/or preventing rheumatoid arthritis in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide ribosi...
|
|
WO/2019/208571A1 |
The present invention provides: an amidite compound represented by formula (1), which enables synthesis of RNA with high purity; and a method for producing a polynucleotide, which uses this compound. (In the formula, R represents a group...
|
|
WO/2019/178393A9 |
The invention provides various orthogonal nucleotide analogues and methods for using combinations of said various orthogonal nucleotide analogues for sequencing by synthesis.
|
|
WO/2019/200273A1 |
The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.
|
|
WO/2019/194385A1 |
The present disclosure relates to a method and apparatus wherein terahertz waves including a first band corresponding to methylation resonance frequency in the terahertz band are applied to methylated molecules and the methylated molecul...
|
|
WO/2019/193543A1 |
The present invention relates to 3'3'-cyclic dinucleotides modified with a 3'-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein (I) or a pharmaceutically acceptable salt thereof wher...
|
|
WO/2019/195494A1 |
The invention provides compositions and methods for synthesis of phosphorylated organic compounds, including nucleoside triphosphates.
|
|
WO/2019/193542A1 |
The present disclosure relates to 2'3'-cyclic dinucleotides modified with a 2'- or 3'-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein (IA) or a compound of Formula (1B) or pharmace...
|
|
WO/2019/193533A1 |
The present invention relates to 2'2'-cyclic dinucleotides modified with a 2'-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein (I) or pharmaceutically acceptable thereof, wherein L1...
|
|
WO/2019/191642A1 |
Provided herein are methods and labeling kits for synthesizing 2'-deoxy-2'-[18F]fluoro-5-methyl-1-beta-D-arabinofuranosyl-u
racil in a one-pot reaction in compliance with CGMP. Also disclosed are labeling kits that can be assembled in an...
|
|
WO/2019/191389A1 |
The invention relates to a crystalline methanol or dimethyl sulfoxide solvated form of regadenoson and an anhydrous polymorph of regadenoson. The invention is also directed to the preparation of the methanol or dimethyl sulfoxide solvate...
|
|
WO/2019/185477A1 |
Compounds of formula I, wherein Base, R1 and R2 are defined as in claim 1, are modulators of STING.
|
|
WO/2019/175126A1 |
The invention comprises LNA-dicarboxylic acid derivatives of the formula I or salts thereof, wherein R1 is a nucleobase or a modified nucleobase R2 is a hydroxy protecting group and n is an integer from 1 to 5. The LNA-dicarboxylic acid ...
|
|
WO/2019/175776A1 |
Compounds of the general formula (I), or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
|
|
WO/2019/174657A1 |
Substituted pyridopyrrolopyrimidine ribonucleosides of general formula I, wherein R is as described in the independent claim, preferably R is selected from the group comprising thiophen-3-yl, furan-2-yl, furan-3-yl, benzofuran-2-yl, meth...
|
|
WO/2019/169837A1 |
The invention relates to an albumin conjunction-type maleimide functionalized gemcitabine prodrug as well as application thereof in transferring an antitumor prodrug. The albumin conjunction-type maleimide functionalized gemcitabine prod...
|
|
WO/2019/172394A1 |
A β-modified phosphoric acid compound precursor having the partial structure represented by formula 1A in the molecule thereof. A medicine and a reaction inhibitor containing the β-modified phosphoric acid compound precursor. (In the f...
|
|
WO/2019/173682A1 |
Methods of identifying compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and that possess particular pharmacokinetic characteristics are described herein. Methods of such compounds, and compositions com...
|
|
WO/2019/171285A1 |
The invention relates to compounds of Formula (I), vvherein R1 is selected from the group consisting of: Formula (Ia) and (Ib) as well as methods of treating or preventing HIV in subjects.
|
|
WO/2019/166457A1 |
The disclosure relates to tagged nucleoside compounds comprising a nucleotide polyphosphate covalently attached to a tag, wherein the compound is a polymerase substrate and the polymer moiety is capable of entering a nanopore linked to t...
|
|
WO/2019/160059A1 |
Provided is a method for recycling s-adenosylmethionine that is characterized in that after s-adenosylmethionine is demethylated, s-adenosylmethionine is regenerated by converting s-adenosylmethionine from methionine obtained by transfer...
|
|
WO/2019/160994A1 |
Methods are provided for the epigenetic analysis of cell-free DNA using organic boranes to convert oxidized 5-methylcytosine residues in the cell-free DNA to dihydrouracil (DHU) residues. Cell-free DNA is contacted with an organic borane...
|
|
WO/2019/160937A1 |
A labeled nucleotide includes a nucleotide, a linking molecule attached to a phosphate group of the nucleotide, and a redox-active charge tag attached to the linking molecule. The redox-active charge tag is to be oxidized or reduced by a...
|
|
WO/2019/155639A1 |
The present invention relates to a production method and a production intermediate for guanosine-3',5'-bisdiphosphate.
|
|
WO/2019/156240A1 |
The present invention relates to a production method and a production intermediate for guanosine-3',5'-bisdiphosphate.
|
|
WO/2019/154388A1 |
The present application relates to a salt of a pyranose-substituted heterocyclic compound, a preparation method therefor, and use thereof, and in particular, to an acid addition salt of a compound of formula (I) or a prodrug thereof, and...
|
|
WO/2019/152911A1 |
Disclosed are compounds having formula (I) or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof, wherein L, Y1, Y2, Y3, Y4, Y5, Z1, Z2, Z3, Z4, Z5, Z6, and Effector are each as defined in the specificatio...
|
|
WO/2019/152416A1 |
Provided herein are compounds of Formula (I) and their salts, and compositions comprising such compounds that are useful for increasing the amount of NAD+ in cells. Also disclosed are methods of using the disclosed compounds and composit...
|
|
WO/2019/147050A1 |
The present invention relates to: novel nucleoside or nucleotide derivatives, racemates thereof, stereoisomers thereof, or pharmaceutically acceptable salts thereof; and a pharmaceutical composition for preventing or treating viral infec...
|
|
WO/2019/143860A1 |
Provided herein are 5-fluorouracil derived acetal and hemiaminal ether compounds, their preparation and their uses, such as treating liver diseases or various types of cancer.
|
|
WO/2019/142135A1 |
The present invention relates to a process for preparing tc-DNA nucleoside precursors, the resulting tc-DNA nucleosides, and oligonucleotides comprising such tc-DNA nucleosides. In an embodiment of the invention, the process includes use...
|
|
WO/2019/139920A1 |
Provided herein are phosphor(n)amidatacetal and phosph(on)atacetal compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in the molecular pathways in the liver.
|
|
WO/2019/137971A1 |
The present invention relates to a compound of the general formula (I) wherein the pyranose ring is a-D-galactopyranose, R1 is selected from the group consisting of (II) wherein the asterix 1 * indicates the carbon atom of the heteroarom...
|
|
WO/2019/140365A1 |
The present invention provides prodrugs and methods of use thereof.
|
|
WO/2019/136389A1 |
The invention relates to nucleotide prodrugs and pharmaceutical preparations thereof. The invention further relates using the prodrugs of the invention in the treatment of mitochondrial DNA (mtDNA) depletion syndrome (MDS).
|
|
WO/2019/135405A1 |
A method for detecting an analog that is derived from trifluridine, the method including a step for subjecting a sample that includes trifluridine or a salt thereof to high-speed liquid chromatography that uses a mobile phase that compri...
|
